The clinical meaning of walking speed as measured by the Timed 25-Foot Walk in patients with multiple sclerosis

JAMA Neurology

Volumn 71, Issue 11, 2014, Pages 1386-1393

  Cohen, Jeffrey A ^a   Krishnan, Arun V ^b   Goodman, Andrew D ^c   Potts, James ^d   Wang, Ping ^d   Havrdova, Eva ^e   Polman, Chris ^f   Rudick, Richard A ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d BIOGEN   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB; PLACEBO; BETA INTERFERON; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; EVALUATION STUDY; HEALTH STATUS INDICATOR; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; PATIENT MONITORING; PHYSICAL COMPONENT SUMMARY SCORE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCORING SYSTEM; SHORT FORM 36; TIMED 25 FOOT WALK; WALKING AID; WALKING SPEED; ADOLESCENT; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; TASK PERFORMANCE; WALKING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TASK PERFORMANCE AND ANALYSIS; WALKING; YOUNG ADULT;

EID: 84919398858     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1895     Document Type: Article

References (32)

1. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438.
2. Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin. 2010;26(1):109-119.
3. Panitch H, Applebee A. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opin Pharmacother. 2011;12(10):1511-1521.
4. Pike J, Jones E, Rajagopalan K, Piercy J, Anderson P. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol. 2012;12(1):94. doi:10.1186/1471-2377-12-94.
5. Yildiz M. The impact of slower walking speed on activities of daily living in patients with multiple sclerosis. Int J Clin Pract. 2012;66(11):1088-1094.
6. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14(7):988-991.
7. Polman CH, Rudick RA. The Multiple Sclerosis Functional Composite: a clinically meaningful measure of disability. Neurology. 2010;74(17)(suppl 3):S8-S15.
8. Kieseier B, Pozzilli C. Assessing changes in walking ability in multiple sclerosis. Mult Scler. 2012; 18(7):914-924.
9. Ontaneda D, LaRocca N, Coetzee T, Rudick R; NMSS MSFC Task Force. Revisiting the Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. Mult Scler. 2012;18(8):1074-1080.
10. Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler. 2004;10(1):55-60.
11. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite. Mult Scler. 2000;6(4):286-290.
12. Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler. 2006;12(5):594-598.
13. Schwid SR, Goodman AD, McDermottMP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology. 2002;58(8):1294-1296.
14. van Winsen LML, Kragt JJ, Hoogervorst ELJ, Polman CH, Uitdehaag BMJ. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler. 2010;16(5):604-610.
15. Contelloe L, Hutchinson M. Is a 20% change in MSFC components clinically meaningful [comment]? Mult Scler. 2007;13(8):1076.
16. Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-FootWalk Test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin. 2012;28(1):49-56.
17. Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-Foot Walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509-1517.
18. Polman CH, O'Connor PW, Havrdova E, et al AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
19. Rudick RA, Stuart WH, Calabresi PA, et al SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
20. Cohen JA, Cutter GR, Fischer JS, et al IMPACT Investigators. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5):679-687.
21. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: Health Institute, New England Medical Center; 1993.
22. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler. 1999;5(4):251-259.
23. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Multiple Sclerosis Functional Composite (MSFC) Administration and Scoring Manual, Revised. National Multiple Sclerosis Society; 2001. http://main.nationalmssociety.org/docs/HOM/MSFC-Manual-and-Forms.pdf. Accessed July 31, 2014.
24. Norman GR, Sloan JA,Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-592.
25. Phan-Ba R, Pace A, Calay P, et al. Comparison of the Timed 25-Foot and the 100-Meter Walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair. 2011;25(7):672-679.
26. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 Health Survey. Lincoln, RI: QualityMetric Inc; 2000.
27. Rajagopalan KP, Jones E, Pike J, Jackson J. Emergence of walking and mobility problems among patients with multiple sclerosis and its impact on quality of life: a cross-sectional assessment in 5 EU countries [abstract]. Mult Scler. 2010;16(suppl 10):S335.
28. Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One. 2013;8(1):e54756. doi:10.1371/journal.pone.0054756.
29. Cohen JT. Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):595-603.
30. Coleman C, Sidovar M, Roberts M, Baker W. Walking speed and health-related quality of life in multiple sclerosis [abstract]. Intl J MS Care. 2012;14 (suppl 2):29.
31. Bosma LV, Kragt JJ, Brieva L, et al. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult Scler. 2010;16(7):862-867.
32. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988;69(10):850-854.